Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INCALDR · Entity 154258 | Director | May 23, 2018 | May 25, 2018 |
| Calithera Biosciences, Inc.CALA · Entity 113073 | Director | January 27, 2023 | January 31, 2023 |
| Disc Medicine, Inc.FSDC · Entity 2273 | Director | August 11, 2020 | August 12, 2020 |
| Freenome, Inc.FRNM · Entity 4644 | Director | July 20, 2026 | July 28, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
| Mereo BioPharma Group plcMREO · Entity 7264 | Director | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALDER BIOPHARMACEUTICALS INC
Report date May 23, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2028-05-22 | Direct | 15,000 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.
Calithera Biosciences, Inc.
Report date January 27, 2023 · Filed January 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDelphi Ventures VIII, L.P. | 0 |
Reported balance
After 2023-01-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-01-27 · Sale · Disposed 120,161 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2: The reported securities were directly held by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of DV VIII and was deemed to have sole voting and dispositive power over the securities held by DV VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDelphi BioInvestments VIII, L.P. | 0 |
Reported balance
After 2023-01-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-27 · Sale · Disposed 1,172 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3: The reported securities were directly held by Delphi BioInvestments VIII, L.P. ("DBI VIII"). DMP VIII is the general partner of DBI VIII and was deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2: The reported securities were directly held by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of DV VIII and was deemed to have sole voting and dispositive power over the securities held by DV VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.
F3: The reported securities were directly held by Delphi BioInvestments VIII, L.P. ("DBI VIII"). DMP VIII is the general partner of DBI VIII and was deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.
Disc Medicine, Inc.
Report date August 11, 2020 · Filed August 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-08-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Freenome, Inc.
Report date July 20, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,918 |
Reported balance
Holding disclosure · report date 2026-07-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,918 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91 · Expires 2031-12-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F4: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F1: The shares subject to this option are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91 · Expires 2032-06-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F1: The shares subject to this option are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.92 · Expires 2033-09-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F2: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from June 28, 2023, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.24 · Expires 2034-03-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 2, 2024, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-05-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F1: The shares subject to this option are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2035-10-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F1: The shares subject to this option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option are fully vested.
F2: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from June 28, 2023, subject to the Reporting Person's continued service on each such vesting date.
F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 2, 2024, subject to the Reporting Person's continued service on each such vesting date.
F4: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,508 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 15,508 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
Mereo BioPharma Group plc
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26 | Direct | 66,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OncoMed Pharmaceuticals Inc
Report date April 23, 2019 · Filed April 23, 2019
Section 16 reporting ended · disclosed 2019-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Delphi Ventures VIII, L.P. | 0 |
Reported balance
After 2019-04-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-04-23 · Other · Disposed 1,991,602 · Balance 0 F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. F3: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi VIII Funds"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Delphi BioInvestments VIII, L.P. | 0 |
Reported balance
After 2019-04-23 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-04-23 · Other · Disposed 18,940 · Balance 0 F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. F3: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi VIII Funds"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.
F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.
F3: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi VIII Funds"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein.
PARDES BIOSCIENCES, INC.
Report date December 23, 2021 · Filed December 30, 2021 · Amendment
Section 16 reporting ended · disclosed 2021-12-30. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2021-12-23 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-12-23 · Conversion · Acquired 30,000 · Balance 30,000 F1: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-12-23 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2021-12-23 · Conversion · Disposed 30,000 · Balance 0 F1: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 58,065 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.66 · Expires 2030-06-30 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-23 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2023 Filed Jan 31, 2023 19:04 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | SaleCommon Stock | 120,161 | $0.39 | $46,358.11 |
DisclosureSEC source: 0000899243-23-003071 · doc4.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Delphi Ventures VIII, L.P. Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · ownership.nature: The reported securities were directly held by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of DV VIII and was deemed to have sole voting and dispositive power over the securities held by DV VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and were deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 13 | $6.00 | $78.02 |
DisclosureSEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 6 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 16,673 F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,294 | $6.00 | $7,766.46 |
DisclosureSEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 5 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,707,549 F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,045 | $6.18 | $12,637.69 |
DisclosureSEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 4 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 16,686 F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 209,455 | $6.18 | $1,294,390.01 |
DisclosureSEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 3 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,708,843 F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,152 | $6.50 | $20,498.40 |
DisclosureSEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,731 F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 322,825 | $6.50 | $2,099,427.82 |
DisclosureSEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,918,298 F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000899243-22-020935 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. F2 · ownership.direct: Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-22-030983 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 01:26 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001415889-22-004336 · form4-04282022_060457.xml · derivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 01:26 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004336 · form4-04282022_060457.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,747 Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:00 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | ConversionClass B Common Stock · Derivative | 52,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067726 · ownership.xml · derivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 52,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. F1 · derivative.exercise_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. F1 · derivative.expiration_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:00 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | ConversionClass A Common Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067726 · ownership.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. Read SEC document |
| December 23, 2021 Filed Dec 30, 2021 21:00 UTC Amendment | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | ConversionClass B Common Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-068105 · ownership.xml · derivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. F1 · derivative.exercise_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. F1 · derivative.expiration_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. Read SEC document |
| December 23, 2021 Filed Dec 30, 2021 21:00 UTC Amendment | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | ConversionClass A Common Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-068105 · ownership.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0000899243-21-023539 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 11, 2021, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. F2 · ownership.direct: Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035030 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001179110-21-004706 · edgar.xml · derivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004706 · edgar.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,895 Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $20.66 | $0.00 |
DisclosureSEC source: 0001179110-20-008053 · edgar.xml · derivative · entry 3 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires 2020-06-30 F2 · derivative.exercise_date: This option shall vest monthly over ten months of service from the date of grant and will vest in full upon the earlier of the ten-month anniversary of Dr. Pakianathan's appointment to the Board or the date of the Company's 2021 annual meeting of shareholders. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $20.66 | $0.00 |
DisclosureSEC source: 0001179110-20-008053 · edgar.xml · derivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option vests monthly over 24 months of service from the date of grant. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008053 · edgar.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,067 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 16:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000899243-20-016148 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 9, 2020, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. F2 · ownership.direct: Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:24 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0001209191-20-032011 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 12:59 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001209191-19-035378 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 6, 2020, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:06 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.42 | $0.00 |
DisclosureSEC source: 0000899243-19-015384 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from May 30, 2019, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. F2 · ownership.direct: Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| April 23, 2019 Filed Apr 23, 2019 16:15 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | OtherCommon Stock | 18,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-010986 · doc4.xml · nonDerivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Delphi BioInvestments VIII, L.P. Disclosed balance after: 0 F1 · price: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2 · price: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. F3 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi VIII Funds"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| April 23, 2019 Filed Apr 23, 2019 16:15 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | OtherCommon Stock | 1,991,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-010986 · doc4.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Delphi Ventures VIII, L.P. Disclosed balance after: 0 F1 · price: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2 · price: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. F3 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi VIII Funds"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 18:10 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001140361-18-029842 · doc1.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-18-038746 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 19, 2019, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:09 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-18-014885 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-05-30 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from May 31, 2018, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. F2 · ownership.direct: Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| May 23, 2018 Filed May 25, 2018 17:16 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001209191-18-033589 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:50 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-17-040570 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 16:37 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000899243-17-016236 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 9, 2017, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. F2 · ownership.direct: Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 17:48 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001140361-17-023644 · doc1.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 19:02 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001209191-17-036029 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.